Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of antiretroviral and tuberculosis drugs during pregnancy and postpartum
PACTR202012605595028Phase 4Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dolutegravir, atazanavir, darunavir, lopinavir, ritonavir and 6 more in human immunodeficiency virus infection (HIV) and Tuberculosis (TB) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Maternal breast milk to maternal plasma concentration ratio, Infant plasma concentration and 1 more. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
dolutegraviratazanavirdarunavirlopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202012605595028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202012605595028.